MARKET

CYTHW

CYTHW

CYCLO THERAPEUT
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.805
-0.195
-6.50%
Closed 16:00 05/18 EDT
OPEN
3.060
PREV CLOSE
3.000
HIGH
3.094
LOW
2.550
VOLUME
1.62K
TURNOVER
--
52 WEEK HIGH
11.94
52 WEEK LOW
0.5000
MARKET CAP
--
P/E (TTM)
-0.4659
1D
5D
1M
3M
1Y
5Y
BRIEF-Cyclo Says On Track To File IND For Phase 2 Study Of Alzheimer's Disease In H2
reuters.com · 1d ago
BRIEF-Cyclo Therapeutics Announces Design Of Pivotal Phase 3 Study Evaluating Trappsol Cycl In Niemann-Pick Type C1
reuters.com · 04/27 13:34
BRIEF-Cyclo Therapeutics Files For Mixed Shelf Of Up To $100 Mln
reuters.com · 03/19 20:09
BRIEF-Cyclo Therapeutics Reports Q4 And FY20 Financial Results
reuters.com · 03/15 12:51
BRIEF-Cyclo Therapeutics Receives Positive Opinion From European Medicines Agency On The Agreement Of A Paediatric Investigation Plan For Trappsol Cyclo
reuters.com · 03/09 16:50
BRIEF-Cyclo Therapeutics Announces Last Patient Last Visit In Phase 1/2 Trial Evaluating Trappsol Cyclo For The Treatment Of Niemann-Pick Disease Type C
reuters.com · 03/04 14:31
BRIEF-Cyclo Therapeutics Presents Positive Data From Clinical Development Program For Lead Candidate, Trappsol Cyclo, At WORLDSymposium 2021
reuters.com · 02/09 13:12
Cyclo Therapeutics Announces Closing of Underwriters Option to Purchase Additional Shares of Common Stock in Connection with its Underwritten Public Offering
Business Wire · 12/22/2020 19:30
More
Forecast
No Data
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CYTHW. Analyze the recent business situations of CYCLO THERAPEUT through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About CYTHW
Cyclo Therapeutics, Inc. is a clinical stage biotechnology company. The Company develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease. The Company’s Trappsol Cyclo, an orphan drug designated product in the United States and Europe, is the subject of three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease. NPC is a fatal cholesterol metabolism disease that impacts the brain, lungs, liver, spleen, and other organs. The Company also sells cyclodextrins and related products to the pharmaceutical, nutritional and other industries, primarily for use in diagnostics and specialty drugs. It serves chemical products directly to customers in the pharmaceutical, diagnostics, and industrial chemical industries, and to chemical supply distributors.

Webull offers kinds of Cyclo Therapeutics Inc stock information, including NASDAQ:CYTHW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYTHW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CYTHW stock methods without spending real money on the virtual paper trading platform.